Orgenesis Reports 143% Increase in Revenue and 316% Increase in Gross Profit for the Third Quarter of Fiscal 2018
October 15 2018 - 8:30AM
CDMO segment achieves operating profit of $2.1
million
Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and
developer of advanced cell therapies, today reported financial
results and provided a business update for the fiscal third quarter
ended August 31, 2018.
Fiscal Q3 2018 financial highlights
include:
- Revenue increased 143% to $6.2 million, as compared to $2.6
million for the same period last year.
- Gross profit increased 310% to $2.9 million, as compared to
$695,000 for the same period last year.
- Gross margin increased to 45.7%, versus 27.1% for the third
quarter of 2017.
- CDMO segment recorded an operating profit of $2.1 million.
- Quarter ended with $16.7 million of cash and approximately $30
million of shareholders’ equity.
Vered Caplan, CEO of Orgenesis, commented, “We
continue to generate strong growth and achieved record revenue of
$6.2 million for the third quarter of 2018. At the same time,
we continue to expand our gross margin, and generated gross profit
of $2.9 million, a 310% increase over the same period last
year. We attribute this growth to the traction our CDMO
segment is gaining within the marketplace, among both new
customers, as well as expanded services among our existing
customers. I am especially pleased to report that our CDMO segment
achieved an operating profit of $2.1 million for the third quarter
of 2018. On the heels of our recent financing with a leading
healthcare fund, we now have over $16.7 million of cash, positive
working capital and approximately $30 million of shareholders’
equity. Overall, we believe that we are well positioned
heading into the fourth quarter and 2019.”
“In addition to our strong financial
performance, we achieved a number of important operational
milestones as we further evolve our business. Specifically,
we are aligning ourselves with regional partners in order to set up
a network of leading healthcare facilities with interest in
developing our autologous cell therapy products. Our goal is
to leverage our IP, technical and manufacturing expertise to allow
a closed system manufacturing approach for our development stage
products. Towards this end, we announced a collaboration with
Secant Group to develop and commercialize biodegradable and
injectable scaffold technologies. We also announced a
partnership with BGN Technologies and the National Institute for
Biotechnology in the Negev, both affiliates of Ben-Gurion
University of the Negev, to develop and commercialize a novel
alginate scaffold technology for cell transplantation, with an
initial focus on autoimmune diseases. We are expanding our
geographic focus and recently announced a license agreement with
HekaBio K.K. to collaborate in the clinical development and
commercialization of regeneration and cell and gene therapeutic
products in Japan. Over the next few quarters, we look
forward to further elaborating on our efforts to develop a
point-of-care collaboration model, including partnerships to expand
our footprint, licensing of new therapies, and the addition of new
production technologies.”
Financial Results
Revenue for the three months ended August 31,
2018 increased 143% to $6.2 million, as compared to $2.6 million
for the three months ended August 31, 2017. Gross profit
increased to $2.9 million for the three months ended August 31,
2018, as compared to $695,000 for the same period last year.
Operating loss was $645,000 for the three months ended August 31,
2018, as compared to $3.4 million for the same period last
year. The Company achieved an operating profit of $2.1
million within its CDMO segment compared to an operating loss of
$124,000 for the same period last year. Net loss for the
three months ended August 31, 2018 was $5 million, or $0.35 per
diluted share, as compared to $3.9 million or $0.40 per diluted
share for the three months ended August 31, 2017.
As of August 31, 2018, the Company reported
$16.7 million of cash and $30 million of shareholders’ equity.
Complete financial results are available in the
Company’s Quarterly report on Form 10-Q filed with the Securities
and Exchange Commission on October 12, 2018, which is available on
the Company’s website at www.orgenesis.com or at www.sec.gov.
About Orgenesis
Orgenesis is a vertically-integrated
biopharmaceutical company with expertise and unique experience in
cell therapy development and manufacturing. Through its
Israeli subsidiary, Orgenesis Ltd., Orgenesis is developing
technology designed to successfully reprogram human liver cells
into glucose-responsive, fully functional, Insulin Producing Cells
(IPCs). Orgenesis believes that converting the diabetic
patient's own tissue into insulin-producing cells has the potential
to overcome the significant issues of donor shortage, cost and
exposure to chronic immunosuppressive therapy associated with islet
cell transplantation. Through its Masthercell Global
subsidiary, a global contract development and manufacturing
organization (CDMO), Orgenesis is able to deliver optimized process
industrialization capacities to cell therapy organizations and
speed up the arrival of their therapies onto the market. From
technology selection to business modeling, GMP manufacturing,
process development, quality management and assay development,
Masthercell’s teams are fully committed to helping their clients
fulfill their objective of providing sustainable and affordable
therapies to their patients. Masthercell operates in a
validated and flexible facility located in the strategic center of
Europe within the Walloon healthcare cluster, Biowin. This
integrated approach supports the Company's business philosophy of
bringing to market significant life-improving medical
treatments. For more information, visit
www.orgenesis.com.
Notice Regarding Forward-Looking
Statements
This press release contains forward-looking
statements which are made pursuant to the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended and Section
21E of the Securities and Exchange Act of 1934, as amended.
These forward-looking statements involve substantial uncertainties
and risks and are based upon our current expectations, estimates
and projections and reflect our beliefs and assumptions based upon
information available to us at the date of this release. We
caution readers that forward-looking statements are predictions
based on our current expectations about future events. These
forward-looking statements are not guarantees of future performance
and are subject to risks, uncertainties and assumptions that are
difficult to predict. Our actual results, performance or
achievements could differ materially from those expressed or
implied by the forward-looking statements as a result of a number
of factors, including, but not limited to, the success of our
reorganized CDMO operations, the success of our partnership with
Great Point, our ability to achieve and maintain overall
profitability, the sufficiency of working capital to realize our
business plans, the development of our transdifferentiation
technology as therapeutic treatment for diabetes which could, if
successful, be a cure for Type 1 Diabetes; our technology not
functioning as expected; our ability to retain key employees; our
ability to satisfy the rigorous regulatory requirements for new
procedures; our competitors developing better or cheaper
alternatives to our products and the risks and uncertainties
discussed under the heading "RISK FACTORS" in Item 1 of our Annual
Report on Form 10-K for the fiscal year ended November 30, 2017,
and in our other filings with the Securities and Exchange
Commission. We undertake no obligation to revise or update
any forward-looking statement for any reason.
ContactsDavid WaldmanCrescendo
Communications, LLCTel: 212-671-1021Orgs@crescendo-ir.com
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Apr 2023 to Apr 2024